Amphastar P (29A)

Currency in EUR
19.1450
+0.4500(+2.41%)
Closed·
29A Scorecard
Full Analysis
Management has been aggressively buying back shares
29A is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
19.145019.1450
52 wk Range
17.240049.7000
Key Statistics
Bid/Ask
18.915 / 19.445
Prev. Close
18.695
Open
19.145
Day's Range
19.145-19.145
52 wk Range
17.24-49.7
Volume
-
Average Volume (3m)
100
1-Year Change
-51.38%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
29A Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Amphastar P News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Amphastar P Company Profile

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Employees
2028
Market
Germany

Compare 29A to Peers and Sector

Metrics to compare
29A
Peers
Sector
Relationship
P/E Ratio
7.5x−2.9x−0.5x
PEG Ratio
−1.58−0.120.00
Price/Book
1.4x0.7x2.6x
Price / LTM Sales
1.5x0.8x3.2x
Upside (Analyst Target)
-30.4%41.6%
Fair Value Upside
Unlock40.5%6.0%Unlock

Earnings

Latest Release
May 08, 2025
EPS / Forecast
0.51 / --
Revenue / Forecast
170.53M / --
EPS Revisions
Last 90 days

29A Income Statement

People Also Watch

104.08
CRUS
+2.88%
22.51
TDC
+2.04%
26.86
CNC
-5.39%
216.59
LULU
-1.29%
30.10
YOU
+1.24%

FAQ

What Stock Exchange Does Amphastar P Trade On?

Amphastar P is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Amphastar P?

The stock symbol for Amphastar P is "29A."

What Is the Amphastar P Market Cap?

As of today, Amphastar P market cap is 901.58M.

What Is Amphastar P's Earnings Per Share (TTM)?

The Amphastar P EPS (TTM) is 2.93.

From a Technical Analysis Perspective, Is 29A a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Amphastar P Stock Split?

Amphastar P has split 0 times.

How Many Employees Does Amphastar P Have?

Amphastar P has 2028 employees.

What is the current trading status of Amphastar P (29A)?

As of 28 Jul 2025, Amphastar P (29A) is trading at a price of 19.15, with a previous close of 18.70. The stock has fluctuated within a day range of 19.15 to 19.15, while its 52-week range spans from 17.24 to 49.70.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.